- Pressemitteilung BoxID 62313
Capsulution contributes to worldwide nanotech network
Berlin based company becomes member of the European Nanotechnology Trade Alliance (ENTA)
For Capsulution, it is very important to join forces with other players in the field. We need to create larger networking between different nanotech providers on one hand, and with different customer industries on the other hand.” says Alexander Herrmann, CFO at Capsulution. “In addition, we have to clarify “What is nanotechnology about?” to whom, who is not familiar with this new approach. Finally, our membership with ENTA represents a quality feature differentiating Capsulution from other suppliers.”
Together with other leading nanotech companies, Capsulution’s contribution is dedicated to increasing the awareness of consumers, industrial clients and investors with respect to Nanotechnology and its social and economic impact for the society. Del Stark, CEO of ENTA: “We are very proud to have Capsulution as a new member as this company is a leader in the development of new life science products for the pharmaceutical market.”
The European Nanotechnology Trade Alliance (ENTA) represents the interests of its members across Europe ENTA offers an integrated programme aimed at promoting the benefits of nanotechnology and mitigating regulatory and reputational risk for the whole industry and supporting all actions that ensure new nanotechnologies are developed in a safe and responsible manner.
In addition to the above, ENTA represents the interests of nanotechnology businesses across Europe and acts to bridge the gap between industry, governments, science, and importantly, the public in promoting the benefits of nanotechnology.
ENTA works closely with the media and government bodies to express the nanotechnology industry’s views and needs, on for example, legislation, standards, standard operating procedures, and public support.
About Capsulution Pharma AG
Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company implements its worldwide-patented LBL Technology®. Based on their minute size, their functionality and their highly reproducible production process, the tunable capsules can be used in a multitude of different applications. Accordingly, the precision-sized capsules can be made to function in a manner suited to the intended application, and can be given biochemical, electrical, optical and magnetic properties tailored to the individual customer. In order to meet customers’ needs for complete product solutions, Capsulution designated EBARA Corp. as the preferred developer, manufacturer and distributor for automated LBL units. In 2005, the renowned growth consultants Frost & Sullivan awarded the year’s “Product Differentiation Innovation Award” in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.
Weitere Pressemitteilungen dieses Herausgebers
- 22.02.2010 - Into the future with a stronger team
- 17.11.2008 - Capsulution and NanoDel merge their businesses
- 17.11.2008 - Capsulution und NanoDel schließen sich zu Capsulution Pharma zusammen